| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, ... New England Journal of Medicine 381 (18), 1728-1740, 2019 | 1027 | 2019 |
| Targeting FLT3 mutations in AML: review of current knowledge and evidence N Daver, RF Schlenk, NH Russell, MJ Levis Leukemia 33 (2), 299-312, 2019 | 872 | 2019 |
| Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia CC Smith, Q Wang, CS Chin, S Salerno, LE Damon, MJ Levis, AE Perl, ... Nature 485 (7397), 260-263, 2012 | 841 | 2012 |
| Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia BD Smith, M Levis, M Beran, F Giles, H Kantarjian, K Berg, KM Murphy, ... Blood 103 (10), 3669-3676, 2004 | 827 | 2004 |
| AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) PP Zarrinkar, RN Gunawardane, MD Cramer, MF Gardner, D Brigham, ... Blood, The Journal of the American Society of Hematology 114 (14), 2984-2992, 2009 | 705 | 2009 |
| Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML Z Zeng, Y Xi Shi, IJ Samudio, RY Wang, X Ling, O Frolova, M Levis, ... Blood, The Journal of the American Society of Hematology 113 (24), 6215-6224, 2009 | 619 | 2009 |
| FLT3: ITDoes matter in leukemia M Levis, D Small Leukemia 17 (9), 1738-1752, 2003 | 601 | 2003 |
| A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo M Levis, J Allebach, KF Tse, R Zheng, BR Baldwin, BD Smith, ... Blood, The Journal of the American Society of Hematology 99 (11), 3885-3891, 2002 | 595 | 2002 |
| Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ... The Lancet Oncology 18 (8), 1061-1075, 2017 | 509 | 2017 |
| A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy S Knapper, AK Burnett, T Littlewood, WJ Kell, S Agrawal, R Chopra, ... Blood 108 (10), 3262-3270, 2006 | 496 | 2006 |
| Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia F Ravandi, JE Cortes, D Jones, S Faderl, G Garcia-Manero, ... Journal of clinical oncology 28 (11), 1856, 2010 | 470 | 2010 |
| Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse M Levis, F Ravandi, ES Wang, MR Baer, A Perl, S Coutre, H Erba, ... Blood, The Journal of the American Society of Hematology 117 (12), 3294-3301, 2011 | 457 | 2011 |
| Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ... Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013 | 446 | 2013 |
| Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, ... The Lancet Oncology 20 (7), 984-997, 2019 | 433 | 2019 |
| Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3–internal tandem … JE Cortes, H Kantarjian, JM Foran, D Ghirdaladze, M Zodelava, ... Journal of clinical oncology 31 (29), 3681, 2013 | 427 | 2013 |
| Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha. PB Wedegaertner, DH Chu, PT Wilson, MJ Levis, HR Bourne Journal of Biological Chemistry 268 (33), 25001-25008, 1993 | 378 | 1993 |
| FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? M Levis Hematology 2013, the American Society of Hematology Education Program Book …, 2013 | 313 | 2013 |
| Midostaurin approved for FLT3-mutated AML M Levis Blood, The Journal of the American Society of Hematology 129 (26), 3403-3406, 2017 | 308 | 2017 |
| Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide SR McCurdy, JA Kanakry, MM Showel, HL Tsai, J Bolaños-Meade, ... Blood, The Journal of the American Society of Hematology 125 (19), 3024-3031, 2015 | 303 | 2015 |
| FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo T Sato, X Yang, S Knapper, P White, BD Smith, S Galkin, D Small, ... Blood, The Journal of the American Society of Hematology 117 (12), 3286-3293, 2011 | 292 | 2011 |
